The company anticipates releasing initial data this year showing that is cancer of unknown primary origin test can successfully guide treatment decisions.
The results suggest comprehensive sequencing like Foundation Medicine's could potentially help improve outcomes for patients with widespread cancer of unknown primary origin.
This story has been updated to clarify the current state of the Tissue of Origin test formerly of Pathwork Diagnostics, now owned and marketed by Response Genetics.
Rosetta Genomics this week announced the publication of data demonstrating the involvement of certain microRNAs in epithelial-mesenchymal transition, or EMT, in cancers of unknown primary origin.
NEW YORK (GenomeWeb News) –Rosetta Genomics today announced it has executed credentialing agreements with two preferred provider organizations for its Cancer Origin Test.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.
